|
Antibody-Based Blood Test for HEG1 Detection
Application
HEG1 as a potential biomarker for early detection and risk assessment of hypertension and atherosclerosis.
Key Benefits
Addresses the importance of HEG1 in hypertension and atherosclerosis.
Diagnostic for use in ELISA.
A potential therapeutic target to treat hypertension and atherosclerosis.
Market Summary
Hypertension, defined...
Published: 7/21/2026
Contributor(s): Hanjoong Jo, Yerin Kim, Michael Clark, Shoutaro Tsuji
|
|
Engineering Asymmetrically Glycosylated IgG Antibodies
Application
A method to produce asymmetrically glycosylated antibodies for the treatment and prevention of diseases including cancer, auto-immune disorders, and infectious diseases.
Key Benefits
This strategy has potential to produce a new class of therapeutic antibodies for treating and preventing a wide range of human diseases.
Market Summary
Monoclonal...
Published: 7/21/2026
Contributor(s): Tala Azzam, Eric J. Sundberg, Jonathan Du, Diego Sastre
|
|
MPL Protein Targeting for Cancer Therapy and Transplant Preparation
Application
Non-genotoxic hematopoietic stem cell transplantation conditioning regimen.
Key Benefits
Selective depletion of hematopoietic stem cells creates adequate niche space to allow donor engraftment without significant off target effect.
Non-genotoxic conditioning regimen.
CAR-T cells can have an anti-MPL positive leukemia effect before...
Published: 7/21/2026
Contributor(s): Shanmuganathan (Shan) Chandrakasan, H. (Harold) Trent Spencer, Christopher Doering, Lauren Fleischer, Gianna Branella, Jaquelyn Zoine, Harrison Brown
|
|
Anticancer Agent with N-Glycan Specificity
Application
An engineered protein for targeting disease-associated N-glycans.
Key Benefits
High affinity, pH insensitive, no cofactors required.
Applications in anticancer and antiviral therapeutics and research.
Can aid in manufacturing monoclonal antibodies with desired N-glycosylation properties.
Market Summary
Glycosylation involves post-translation...
Published: 7/9/2026
Contributor(s): Eric J. Sundberg, Diego Sastre, Maros Huliciak
|
|
Combinatorial Therapy for Preserving Muscle Mass During Weight Loss
Application
A combinatorial therapy to preserve muscle mass during semaglutide weight loss treatment.
Key Benefits
Preserves lean mass during semaglutide treatment in preclinical mouse models.
Increases overall fat loss without affecting food/water intake during semaglutide treatment in preclinical mouse models.
Market Summary
The prevalence...
Published: 7/21/2026
Contributor(s): Todd Golde, Yong Ran, Eric Krause, Annette De Kloet, Karen Scott
|
|
Anti-Green Fluorescent Protein Antibodies
Applications
Western Blot
Immunocytochemistry
Immunohistochemistry
Specificity
Vertebrates
Subtype
Chicken Polyclonal
Immunogen
His-tagged green fluorescent protein of the bioluminescent hydrozoan jellyfish (Aequorea Victoria).
Technical Summary
Drs. Tomasiewicz, Wood, & Flaherty have created a polyclonal anti- green fluorescent...
Published: 5/26/2026
Contributor(s): Henry Tomasiewicz, John Wood, Denise Flaherty
|
|
EF-Tu Targeting Antibody for Infection Treatment
Application
Therapeutic monoclonal antibodies directed to Elongation Factor-Tu (EF-Tu) for the treatment of infections.
Key Benefits
An antibody that targets the protein EF-Tu, which is present on many types of bacteria involved in life-threatening infections.
A research-grade antibody has been developed with animal data showing the ability to...
Published: 9/22/2025
Contributor(s): Joanna Goldberg, Dina Moustafa
|
|
BG505 SOSIP Vaccine Elicited Neutralizing Monoclonal Antibodies for HIV
Application
ELISA
Western Blot
Immunohistochemistry
Specficity
HIV-1 BG505 Env protein (clone name: YRK01, YRK02).
Subtype
Monoclonal antibody.
Immunogen
HIV-1 BG505 SOSIP Env trimer.
Technical Summary
HIV-1 envelope glycoprotein (Env) is a membrane protein complex involved in receptor recognition and viral fusion with CD4+ T cells...
Published: 1/20/2026
Contributor(s): Cynthia Derdeyn, Tysheena Charles
|
|
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application
Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients.
Key Benefits
Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 7/21/2026
Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
|
|
Trimeric Immunogen for HIV-1 Vaccination
Application
Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine.
Key Benefits
Possible oral administration.
Broadly cross-reactive against HIV-1 panel.
Promotes antibody responses as both a primary immunogen and boosting immunogen.
Market Summary
Antiretroviral therapy (ART) has dramatically prolonged...
Published: 7/21/2026
Contributor(s): Rama Rao Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
|
